Abstract: In the revised 2016 WHO Classification of Lymphoid Neoplasms, double expressor lymphoma (DEL) is defined as a diffuse large B-cell lymphoma (DLBCL) with increased expression of Myc and Bcl-2 proteins which is uncorrelated with chromosomal rearrangements. DEL is not an independent diagnostic category. It is still considered to be a DLBCL not otherwise specified (DLBCL-NOS). Many studies on the prognosis and treatment of DEL patients have deepened our understanding of this disease, including studies of the impact of different cut-offs for Myc and Bcl-2 protein overexpression; the prognostic value of TP53, CD5, and serum albumin; and explorations of intensive chemotherapy, hematopoietic stem cell transplantation, targeted therapies, immunotherapies, etc. The purpose of this review is to discuss the prognostic factors and current therapeutic approaches for patients with DEL.